{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:38:53Z","timestamp":1792471133126,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis of COMBINE 1\u20133 assessed efficacy and hypoglycaemia outcomes with IcoSema (once\u2010weekly combination therapy of basal insulin icodec and semaglutide [a glucagon\u2010like peptide\u20101 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Treatment outcomes were analysed by trial according to kidney (estimated glomerular filtration rate \u2265\u200990; 60\u2013&lt;\u200990; 30\u2013&lt;\u200960; &lt;\u200930\u2009\n                      <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                      \/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      ) and liver (total bilirubin \u2264\u200921\u2009\u03bcmol\/L or aspartate aminotransferase [\n                      <jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>\n                      ] \u2264\u200931\/\u2264\u200937 [female\/male] U\/L; total bilirubin &gt;\u200921\u2009\u03bcmol\/L or\n                      <jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>\n                      &gt;\u200931\/&gt;\u200937 [female\/male] U\/L) function subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In COMBINE 1\u20133, across kidney and liver function subgroups, there were no statistically significant treatment by subgroup interactions for change in glycated haemoglobin (HbA1c) (baseline to week 52), change in body weight (baseline to week 52) or rates of combined clinically significant or severe hypoglycaemia (not assessed by kidney function for COMBINE 2) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). There were statistically significant treatment by kidney function subgroup interactions for the achievement of HbA1c &lt;\u20097.0% without weight gain and without clinically significant or severe hypoglycaemia in COMBINE 3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) but not COMBINE 1 or 2, and statistically significant treatment by liver function subgroup interactions in COMBINE 1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) but not COMBINE 2 or 3. For COMBINE 1 and 3, there were statistically significant treatment by kidney function subgroup interactions for mean weekly total insulin dose, but not statistically significant treatment by liver function subgroup interactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Efficacy and hypoglycaemia outcomes with IcoSema versus comparators were generally consistent among adults with T2D with mild to moderate kidney impairment or impaired liver function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      The COMBINE 1\u20133 trials were sponsored by Novo Nordisk and are registered with\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      (NCT05352815; NCT05259033; NCT05013229)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70895","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T01:41:12Z","timestamp":1785980472000},"page":"9607-9620","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Hypoglycaemia Outcomes With Once\u2010Weekly\n                    <scp>IcoSema<\/scp>\n                    Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A\n                    <i>Post Hoc<\/i>\n                    Analysis of the\n                    <scp>COMBINE<\/scp>\n                    1\u20133 Trials"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-9161","authenticated-orcid":false,"given":"Jonas Dahl","family":"Andersen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Benamar","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ponzani","sequence":"additional","affiliation":[{"name":"SSD Diabetology and Metabolic Diseases, Azienda Sanitaria Locale  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Unnikrishnan","sequence":"additional","affiliation":[{"name":"Chellaram Diabetes Institute  Pune India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Vinther","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela","family":"Rea","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Endocrine Division (SEMPR) Universidade Federal Do Paran\u00e1  Curitiba Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164116683082"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S82008"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01951-9"},{"issue":"1","key":"e_1_2_11_7_1","first-page":"S181","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01405-8"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00096-8"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06348-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11313"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2023.19.1.4"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00052-X"},{"key":"e_1_2_11_16_1","unstructured":"European Medicines Agency \u201cInsulin Icodec (Awiqli) Summary of Product Characteristics \u201d2024 accessed September 22 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/awiqli\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_17_1","unstructured":"European Medicines Agency \u201cSemaglutide (Ozempic) Summary of Product Characteristics \u201d2024 accessed September 22 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ozempic\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303208"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00093-1"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00520-2"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1288"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15045"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002619"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2021.06.008"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16231"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01375-2"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0528-2"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13186"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz023"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03223-z"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70895","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:51:53Z","timestamp":1792468313000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/dom.70895"],"URL":"https:\/\/doi.org\/10.1111\/dom.70895","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2026-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}